Interim Results to be Unveiled by Everest Medicines
Everest Medicines, a publicly listed biopharmaceutical company based in Hong Kong, has announced that it will report its interim financial results for the six months ended June 30, 2025, and provide a business update on August 29, 2025.
The English session of the conference call will be held at 8:00 AM Beijing Time on August 29, and the Mandarin session will follow at 9:30 AM Beijing Time. Participants can dial in using the provided numbers or access the conference calls via the webcast links.
Key developments that may be discussed in the upcoming report include the acceptance of the new drug application for velsipity by the Taiwan Food and Drug Administration for the treatment of moderately to severely active ulcerative colitis. This regulatory milestone could significantly impact the company's financial condition and growth prospects.
Additionally, Everest Medicines recently announced an investment of US$30.9 million in US-based global biotech company I-Mab, which could signal strategic expansion or collaboration opportunities.
The exact financial figures for the August 29 report were not disclosed, but the updates suggest that the interim results will likely cover progress on product development, regulatory advances, venture investments, and their impact on the company's financial condition and growth prospects.
For precise financial outcomes such as revenue, profit/loss, or forecasts, the official August 29 release from Everest Medicines will provide detailed disclosures.
Replay of the English session will be available on the Company's website at http://www.everestmedicines.com, and the webcast links for the Mandarin session can be found at https://s.comein.cn/encsgfgi.
For those in the United States, the dial-in numbers for the English session are 1-646-254-3594, and for the Mandarin session, the password is 899823. For participants in the United Kingdom, the number is 44-12-1368-0466. For international participants, the number is 1-866-636-3243.
In Hong Kong, the numbers are 852-3005-1313 (English) and 852-3005-1355 (Mandarin). For participants in China, the numbers are 86-10-5808-4166 (English) and 86-10-5808-4199 (Mandarin).
The U.S. Eastern Time equivalent for the English session is 8:00 PM on August 28, 2025, and for the Mandarin session, it is 9:30 PM on August 28, 2025.
Interested parties are encouraged to tune in to the conference calls or visit the Company's website for the latest updates on Everest Medicines' financial performance and business developments.
- The interim financial results report by Everest Medicines, scheduled for August 29, 2025, may discuss the impact of strategic investments in technology companies like I-Mab, which could potentially influence the company's financial condition and future business ventures in technology.
- The updates on Everest Medicines' financial health and business advancements, including technology investments and regulatory milestones, are expected to cover key areas such as product development, financial condition, and growth prospects.
